|
|
|
| Ras and ERK1/2 Protein Expression in Cancer Tissues of Patients with Type 2 Diabetes Mellitus and Colorectal Cancer: Significance and Correlation with Lymph Node Metastasis and Survival |
| NIU Shu, DONG Lina, et al |
| The People's Hospital of Shijiazhuang, Hebei Shijiazhuang 050011, China |
|
|
|
|
Abstract Objective: To investigate the expression levels of Ras-ERK1/2 signaling in patients with type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC), analyze their relationship with lymph node metastasis, and explore their correlation with survival status. Methods: A total of 59 patients who underwent colorectal cancer surgery at People's Hospital of Shijiazhuang from March 2019 to January 2021 were selected. Patients were divided into the diabetes group (n=29) and non-diabetes group (n=30) based on the presence of concurrent diabetes. Immunohistochemical methods were used to detect the expression levels of Ras and ERK1/2 proteins in surgically resected cancer tissues. Differences in lymph node metastasis were analyzed using the Log-rank test. All patients were followed up for 36 months, and survival conditions were statistically compared. The Spearman correlation analysis was used to analyze the correlation between Ras and ERK1/2 expression and survival period. Results: Ras and ERK1/2 were expressed in both CRC and CRC combined with T2DM, mainly concentrated in the cytoplasm of cancer cells. Compared with the non-diabetes group, the positive expression rates of Ras and ERK1/2 in the CRC combined with T2DM group were significantly increased (P<0.05). The lymph node metastasis rate in the CRC combined with T2DM group was significantly higher than that in the pure CRC group (P<0.05). Compared with the Ras and ERK1/2 negative expression group, the lymph node metastasis rate was significantly higher in the Ras and ERK1/2 positive expression group (P<0.05). The Spearman correlation analysis showed that the protein expression of Ras and ERK1/2 in colorectal cancer patients was negatively correlated with median survival time (P<0.05). Conclusion: Positive expression of Ras-ERK1/2 proteins is positively correlated with lymph node metastasis and negatively correlated with the survival period of colorectal cancer patients, making it an important target for early diagnosis and prognosis assessment.
|
|
|
|
|
|
[1] 牛姝,张宁,王媛,等.P-ERK1/2在2型糖尿病合并结直肠癌患者癌组织中的表达及意义[J].河北医药,2022,44(6):824-828.
[2] Slack C.Ras signaling in aging and metabolic regulation[J].Nutr Healthy Aging,2017,4(3):195-205.
[3] Schlessinger J.Cell signaling by receptor tyrosine kinases[J].Cell,2000,103(2):211-225.
[4] Bosman F T,Cameiro F,Hruban R H,et al.World health organization classification of tumours of the digestive system[M].Lyon:IARC Press,2010.
[5] Ling S,Brown K,Miksza J K,et al.Association of type 2 diabetes with cancer:a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people[J].Diabetes Care,2020,43,2313-2322.
[6] Giouleme O,Diamantidis M D,Katsaros M G.Is diabetes a causal agent for colorectal cancer Pathophysiological and molecular mechanisms[J].World Gastroenterol,2011,17,444-448.
[7] Hua F,Yu J J,Hu Z W.Diabetes and cancer,common threads and missing links[J].Cancer Lett,2016,374,54-61.
[8] Ryu T Y,Park J,Scherer P E.Hyperglycemia as a risk factor for cancer progression[J].Diabetes Metab,2014,38,330-336.
[9] Samatar AA,Poulikakos PI.Targeting RAS-ERK signalling in cancer:promises and challenges[J].Nat Rev Drug Discov,2014,13(12):928-942.
[10] Drosten M,Barbacid M.Targeting the MAPK pathway in KRAS-driven tumors[J].Cancer Cell,2020,37(4):543-550.
[11] Luo J,Lin H C,He K,et al.Diabetes and prognosis in older persons with colorectal cancer[J].Br Cancer,2014,110 (7):1847-1854. |
|
|
|
2023, Vol. 29 
